Synaptic Systems

Rudolf-Wissell-Str. 28
37079 Göttingen, Germany
Phone: +49 551-50556-0
Fax: +49 551-50556-384
E-mail: sales@sysy.com
Web: www.sysy.com

# Abeta-pE3

**Cat.No. 218 003; Polyclonal rabbit antibody, 50 µg specific antibody (lyophilized)**

## Data Sheet

| | |
|---|---|
| Reconstitution/ Storage | 50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Rabbit serum albumin was added for stabilization. For reconstitution add 50 µl $H_2O$ to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C until use. |
| Applications | **WB**: 1 : 1000 (see remarks)<br>**IP**: not tested yet<br>**ICC**: not tested yet<br>**IHC**: 1 : 500 (see remarks)<br>**IHC-P/FFPE**: 1 : 200 (see remarks) |
| Immunogen | Synthetic peptide corresponding to AA 3 to 7 from human Abeta-pE3 (UniProt Id: P05067) |
| Reactivity | Reacts with: human (P05067), rat (P08592), mouse (P12023).<br>Other species not tested yet. |
| Specificity | Specific for Abeta-pE3. |
| Remarks | **WB**: Detects purified Abeta pE3. Complex samples like brain extracts still have to be tested. Boil membrane after blotting for 3min.<br><br>**IHC**: Formic acid treatment required recommended protocol.<br><br>**IHC-P**: Formic acid treatment required. |

**TO BE USED IN VITRO / FOR RESEARCH ONLY**
**NOT TOXIC, NOT HAZARDOUS, NOT INFECTIOUS, NOT CONTAGIOUS**

Amyloid deposits, also called plaques, of Alzheimer's patients consist of several protein components like the **a**myloid **beta**-peptides (**Abeta**, **Aβ**) 1-40/42 and additional C- and N-terminally truncated and modified fragments. Very abundant are the isoaspartate (isoAsp)-Abeta and **p**yro**glu**tamyl (**pGlu**)-Abeta peptides. The latter are formed by cyclization of the N-terminal glutamate at position 3 or 11 catalyzed by glutaminyl cyclase (QC) resulting in very amyloidogenic and neurotxic variants of Abeta; **Abeta-pE3** and Abeta pE11.
In contrast to extracellular plaques that do not perfectly correlate with Alzheimer´s disease intraneuronal Abeta accumulation and vascular Abeta deposits have gained more and more evidence to be among the crucial factors responsible for progressive neuron loss.

## Selected References SYSY Antibodies

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Rönicke R, Reymann K, et al.
Nature (2012) 485(7400): 651-5. **IHC, WB**

Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
Morawski M, Schilling S, Kreuzberger M, Waniek A, Jäger C, Koch B, Cynis H, Kehlen A, Arendt T, Hartlage-Rübsamen M, Demuth HU, et al.
Journal of Alzheimer's disease : JAD (2014) 39(2): 385-400. **IHC; tested species: human**

Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration.
Becker A, Kohlmann S, Alexandru A, Jagla W, Canneva F, Bäuscher C, Cynis H, Sedlmeier R, Graubner S, Schilling S, Demuth HU, et al.
BMC neuroscience (2013) 14: 108. **IHC; tested species: human**

Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer's disease neuropathology.
Morawski M, Brückner G, Jäger C, Seeger G, Matthews RT, Arendt T
Brain pathology (Zurich, Switzerland) (2012) 22(4): 547-61. **IHC; tested species: human**

Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation.
Alexandru A, Jagla W, Graubner S, Becker A, Bäuscher C, Kohlmann S, Sedlmeier R, Raber KA, Cynis H, Rönicke R, Reymann KG, et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience (2011) 31(36): 12790-801. **IHC**

Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
Hartlage-Rübsamen M, Morawski M, Waniek A, Jäger C, Zeitschel U, Koch B, Cynis H, Schilling S, Schliebs R, Demuth HU, Rossner S, et al.
Acta neuropathologica (2011) 121(6): 705-19. **IHC**

## Selected General References

Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core.
Sullivan CP, Berg EA, Elliott-Bryant R, Fishman JB, McKee AC, Morin PJ, Shia MA, Fine RE
Neuroscience letters (2011) 505(2): 109-12.

Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.
Perez-Garmendia R, Ibarra-Bracamontes V, Vasilevko V, Luna-Muñoz J, Mena R, Govezensky T, Acero G, Manoutcharian K, Cribbs DH, Gevorkian G
Journal of neuroimmunology (2010) 229(1-2): 248-55.

Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, et al.
Nature medicine (2008) 14(10): 1106-11.

Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease.
Hook V, Schechter I, Demuth HU, Hook G
Biological chemistry (2008) 389(8): 993-1006.

Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases.
Böhme L, Hoffmann T, Manhart S, Wolf R, Demuth HU
Biological chemistry (2008) 389(8): 1055-66.

Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ.
Schilling S, Appl T, Hoffmann T, Cynis H, Schulz K, Jagla W, Friedrich D, Wermann M, Buchholz M, Heiser U, von Hörsten S, et al.
Journal of neurochemistry (2008) 106(3): 1225-36.

Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.
Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Rüther E, Kornhuber J, Annaert W, et al.
The Journal of biological chemistry (2001) 276(46): 42645-57.

Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta.
Wood SJ, Maleeff B, Hart T, Wetzel R
Journal of molecular biology (1996) 256(5): 870-7.